Company announcements, media coverage and field notes from the team building disease-modifying therapies for neuroinflammation-driven conditions.
POCD and CICI are real, named conditions affecting millions each year. There are no approved treatments. This is why we built Nulyn Science.
Up to 30% of older surgical patients experience lasting cognitive decline. Most are never warned. Here’s the biology and what patients can do.
Cancer survivors have described it for decades. The neuroinflammatory mechanism behind CICI is finally well understood — and it points to a tractable target.
How drug repurposing changes the economics — and the ethics — of pharmaceutical development, and why 505(b)(2) is the right strategy for POCD and CICI.
POCD doesn’t happen to everyone. Certain factors — age, procedure type, vascular health — make it significantly more likely. Here’s what the evidence says.
What has real evidence, what has uncertain magnitude, and what is probably not worth a patient’s energy. A clear-eyed look at the current landscape.
Understanding the cell at the center of neuroinflammation — and why its dysregulation connects chemobrain, POCD, and Alzheimer’s disease.
We're happy to provide assets, data, executive commentary and background on our programs. We aim to respond to journalist inquiries within one business day.